Sinha, J., Zimmerman, K., Balevic, S. J., Hornik, C., Muller, W. J., Rathore, M., … Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. (2026). Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity. Clin Pharmacokinet. https://doi.org/10.1007/s40262-025-01613-1

Sinha, Jaydeep, Kanecia Zimmerman, Stephen J. Balevic, Chi Hornik, William J. Muller, Mobeen Rathore, Marisa Meyer, et al. “Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity.” Clin Pharmacokinet, January 6, 2026. https://doi.org/10.1007/s40262-025-01613-1.

Sinha J, Zimmerman K, Balevic SJ, Hornik C, Muller WJ, Rathore M, et al. Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity. Clin Pharmacokinet. 2026 Jan 6;

Sinha, Jaydeep, et al. “Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity.” Clin Pharmacokinet, Jan. 2026. Pubmed, doi:10.1007/s40262-025-01613-1.

Sinha J, Zimmerman K, Balevic SJ, Hornik C, Muller WJ, Rathore M, Meyer M, Finkelstein Y, Al-Uzri A, Lakhotia A, Goldstein S, Chen J-Y, Anand R, Gonzalez D, Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity. Clin Pharmacokinet. 2026 Jan 6;